The following discussion and analysis of the financial condition and results should be read together with the unaudited condensed consolidated financial statements and notes thereto that are contained in this Quarterly Report on Form 10-Q as well as our Annual Report on Form 10-K for the fiscal year ended
October 1, 2021and our other filings, including the Current Reports on Form 8-K, that have been filed with the SECthrough the date of this report.
This Quarterly Report on Form 10-Q (this "Quarterly Report") contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a "safe harbor" for statements about future events, products and future financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of
Varex Imaging Corporation("we," "our," "us," the "Company," "Varex," or "Varex Imaging"). Actual results and the outcome or timing of certain events described in these forward-looking statements are subject to risk and uncertainties and may differ significantly from those projected in these forward-looking statements. Important factors that could cause our actual results and financial condition to differ significantly from those projections or expectations include, among other things, the risks described in the Summary of Principal Risk Factors below and further described in the Risk Factors listed in Part II, Item 1A - Risk Factors of this Quarterly Report. Statements concerning: the continuing impact of the ongoing COVID-19 pandemic on the global economy or the Company; logistics, supply chain and manufacturing challenges; industry or market segment outlook; market acceptance of or transition to new products or technology such as advanced X-ray tube and digital flat panel detector products; growth drivers; future orders, revenues, backlog, earnings or other financial results; and any statements using the terms "believe," "expect," "anticipate," "can," "should," "would," "could," "estimate," "may," "intended," "potential," and "possible" or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results and the outcome and timing of certain events to differ materially from those projected or management's current expectations. Any forward-looking statement made in this Quarterly Report (including in any exhibits or documents incorporated by reference) is based only on information currently available to Varex and its management and speaks only as of the date on which it is made. We have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.
Varex Imaging Corporationis a leading innovator, designer and manufacturer of X-ray tubes, digital detectors, linear accelerators and other image software processing solutions, which are critical components in a variety of X-ray based imaging equipment. Our components are used in medical diagnostic imaging, security inspection systems, and industrial quality inspection systems, as well as for analysis and measurement applications in industrial manufacturing applications. Global original equipment manufacturers ("OEMs") incorporate our X-ray imaging components in their systems to detect, diagnose, protect and inspect. Varex has approximately 2,200 full-time equivalent employees, located at manufacturing and service center sites in North America, Europe, and Asia. Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americasincludes North America(primarily the United States) and Latin America. EMEA includes Europe, Russia, the Middle East, Indiaand Africa. APAC includes Asiaand Australia. Revenues by region are based on the known final destination of products sold. Our success depends, among other things, on our ability to anticipate and respond to changes in our markets, the direction of technological innovation and the demand from our customers. We continually invest in research and development and employ approximately 500 individuals in product development related activities. Our focus on innovation and product performance along with strong and long-term customer relationships allows us to collaborate with our customers to bring industry-leading products to the X-ray imaging market. We continue to work to improve the life and quality of our imaging components and leverage our scale as one of the largest independent X-ray imaging component suppliers to provide cost-effective solutions for our customers. 28
Impact of COVID-19 and the general economic environment
The unprecedented nature of the COVID-19 pandemic and its effect on the global economy began to significantly disrupt our business in fiscal year 2020 by initially reducing demand for our products followed by strong recovery in demand but increasing variability in supply of raw materials and manufacturing productivity. During fiscal year 2021, demand for many of our products recovered to pre-pandemic levels and business has continued to grow during fiscal year 2022. We believe that demand for our products has increased due to increased investments in healthcare and diagnostics coupled with end-users (such as hospitals) making capital purchases that were previously deferred due to the uncertainty surrounding COVID-19. While we are encouraged by the recovery, we remain cautious as many factors remain unpredictable. We continue to experience logistics, supply chain, and manufacturing challenges that we expect will continue throughout calendar year 2022. The supply chain challenges related to certain components have become more pronounced, and shortages in raw materials have become more widespread, since the beginning of this calendar year. We continue to experience shortages of certain materials and have used more of our inventory on hand of those materials than we have used historically. In addition, we are purchasing more materials that are critical to our processes, often at higher costs. Shortages of materials, particularly micro-controller chips and associated electronic components, have caused and may continue to cause, delays in manufacturing products for our customers. In some cases, raw material shortages and delivery delays from our suppliers are communicated to us with very little advanced warning, which has caused operational and customer order fulfillment challenges. During fiscal year 2021, inventory levels declined and in fiscal year 2022 it has continued to be difficult to replenish certain components of that inventory. While we are dedicating significant resources to manage, mitigate, and resolve these issues, we currently expect supply chain challenges to continue to impact our ability to deliver products to our customers over the next several quarters. In connection with these supply chain disruptions, we have experienced inflationary increases of certain raw materials, as well as increases in logistics, transportation and labor costs. Increased freight charges and shipping delays became more common during the pandemic and subsequent periods, and are expected to continue into the foreseeable future. Due to the rising cost environment, in addition to ongoing expense management, we have raised prices on certain products. While we expect to make pricing adjustments throughout fiscal year 2022, our margins could be impacted by rising costs. During the three months ended
July 1, 2022, our manufacturing facilities continued to operate without significant disruption due to employee absences. While we have from time to time taken significant precautions to maintain employee safety, such as implementing mask requirements, encouraging vaccination, and periodically asking non-production related employees to work from home when possible, we have experienced and may in the future experience, COVID-19 related employee absences that make it more difficult to manufacture our products. The full extent to which the COVID-19 pandemic and ensuing supply chain challenges have and will directly or indirectly impact us, including our business, financial condition, and results of operations, will depend on future developments that are highly uncertain and cannot be accurately predicted. We will continue to actively monitor the situation and may take further actions that alter our business operations or that we determine are in the best interests of our employees, customers, suppliers, and stockholders. For additional information on risks related to the pandemic and other supply chain risks that could impact our results, see Part II, Item 1A - Risk Factors.
Operating segments and products
We have two operating segments to present: medical and industrial. The segments align our product and service offerings with customer usage in the medical and industrial markets.
Medical In our Medical segment, we design, manufacture, sell and service X-ray imaging components, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers and buckys. These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. Our X-ray imaging components are primarily sold to OEM customers. These OEM customers then design-in our products into their X-ray imaging systems for a variety of medical modalities. A substantial majority of medical X-ray imaging OEMs globally are our customers, and many of these have been our customers for over 25 years. We believe one of the reasons for customer loyalty is that our hardware and software products are tightly integrated with our customers' systems. We work very closely with our customers to create custom built components for their systems based on technology platforms that we have developed. Because our products are often customized for our customers' specific equipment, it can be costly and complex for our customers to switch to another provider. 29
Once our components are designed into our customers' equipment, our customers will typically continue to buy from us for any replacement components and for service and support for that equipment. Some of our products are also included in product registrations for our customers' equipment that require regulatory approval to change. In addition to sales to OEM customers, we sell our products to independent service companies and distributors as well as directly to end-users for replacement purposes. The COVID-19 pandemic had a significant effect on hospitals, clinics and outpatient imaging centers as they encountered declines in elective procedures volume. As a result, they reduced the capital purchases of imaging equipment from OEMs, which led to lower demand for X-ray imaging components for us. Additionally, equipment installations were delayed, due to reduced access to healthcare institutions. Partially offsetting this was an increased demand for imaging equipment used to diagnose respiratory diseases, such as radiographic X-ray imaging systems and CT imaging systems. The Company has experienced growth in demand for its products as health systems globally have continued to address healthcare services gaps. However, the Company has not been able to convert all the demand into sales due to on-going supply chain related interruptions and uncertainties, particularly with the availability of micro-controller chips and other electronic components. As a result, uncertainty in overall sales volume is expected to continue at least for the remainder of calendar year 2022. In
China, the government is broadening the availability of healthcare services. As a result, the number of diagnostic X-ray imaging systems, including CT, has grown significantly. We are developing CT X-ray tubes and related subsystems for Chinese OEMs as they introduce new systems in China. Over the long-term, our objective is to become the partner of choice both for OEMs and in the replacement market as CT systems become more widely adopted throughout the Chinese market. In recent years our business in Chinahas been impacted by the trade war with the United Statesin three principal ways: (1) importing raw materials from Chinato the United Stateshas become more expensive, (2) importing raw materials and sub-assemblies from the United Statesto Chinahas become more expensive, and (3) importing finished U.S.manufactured products into Chinahas become more difficult and expensive. Recently the governments of both the United Statesand Chinahave granted tariff exclusions which temporarily eliminate the additional duties payable for specific commodities, providing partial relief. However, U.S.exclusions possess a calendar year-end expiration and Chinese exclusions must be solicited and approved on a shipment-by-shipment basis. There is no guarantee that such exclusions will be granted or extended by either government. In order to mitigate the impact of tariffs on materials imported from China, we have implemented changes to secure more non- Chinasources of materials used to manufacture our X-ray imaging products. To help mitigate the impact of tariffs, and to be closer to our global customer base, we continue to expand manufacturing capabilities at our facilities in China, Germanyand the Philippines. We have also implemented local sourcing strategies to offer local content. This local-for-local strategy has been well received by both our local customers as well as global OEMs, and acts as a natural hedge against trade wars and other potential supply chain disruptions.
In our Industrial segment, we design, develop, manufacture, sell and service X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders and baggage screening at airports, and nondestructive testing and inspection applications used in a number of other vertical markets. Our industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors and high voltage connectors. In addition, we license proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to our industrial customers. Our Industrial business benefits from the research and development investment and manufacturing economies of scale on the Medical side of our business, as we continue to find new applications for our technology. Along with more favorable pricing dynamics, this allows us to generally achieve higher gross profit for industrial products relative to our Medical business. In addition, our Industrial business benefits from our long-term service agreements for our Linatron® products. The security market primarily consists of cargo security for the screening of trucks, trains, and cargo containers at ports and borders as well as airport security for carry-on baggage, checked baggage and palletized cargo. The end customers for border protection systems are typically government agencies, many of which are in oil-based economies and war zones where there can be significant variation in buying patterns. Non-destructive testing and inspection verticals utilize X-ray imaging to scan items for inspection of manufacturing defects and product integrity in a wide range of industries including the aerospace, automotive, electronics, oil and gas, food packaging, metal castings and 3D printing industries. In addition, new applications for X-ray sources are being developed, such as sterilization of food and its packaging. We provide X-ray sources, digital detectors, high voltage connectors and image processing software to OEM customers, system integrators and manufacturers in a variety of these verticals. We believe that the non-destructive testing market represents a significant growth opportunity for our business, and we are actively pursuing new potential applications for our products. The economic downturn triggered by the COVID-19 pandemic reduced the demand for X-ray imaging equipment utilized in the non-destructive testing market as manufacturers focused on cash preservation and reduced spending for capital equipment. However, we have seen improved conditions in this market, which continued during the three months ended
July 1, 2022. 30
Significant Accounting Policies and Estimates
The preparation of our condensed consolidated financial statements and related disclosures in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. Our critical accounting policies that are affected by accounting estimates require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. We periodically review our accounting policies, estimates and assumptions and make adjustments when facts and circumstances dictate. Refer to our Annual Report on Form 10-K for the fiscal year ended
October 1, 2021filed with the SECon November 19, 2021and Note 1, Summary of Significant Accounting Policies, of the notes to the condensed consolidated financial statements of this report for further details. Our critical accounting policies that are affected by accounting estimates include valuation of inventories, assessment of recoverability of goodwill and intangible assets, and income taxes. Such accounting policies require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. There have been no changes to our critical accounting policies, estimates and assumptions or the judgments affecting the application of those estimates and assumptions since the filing of our Annual Report on Form 10-K for year ended October 1, 2021. Fiscal Year The fiscal years of the Company as reported are the 52 or 53-week period ending on the Friday nearest September 30. Fiscal year 2022 is the 52-week period ending September 30, 2022. Fiscal year 2021 was the 52-week period that ended on October 1, 2021. The fiscal quarters ended July 1, 2022and July 2, 2021were both 13-week periods. The three fiscal quarters ended July 1, 2022and July 2, 2021were both 39-week periods.
Discussion of operating results for the three months ended
Compared to the three months ended
Revenues, net Three Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change % Change Medical
$ 167.1 $ 167.3 $ (0.2)(0.1) % Industrial 47.4 43.9 3.5 8.0 % Total revenues $ 214.5 $ 211.2 $ 3.31.6 % Medical as a percentage of total revenues 77.9 % 79.2 % Industrial as a percentage of total revenues 22.1 % 20.8 % Medical revenues decreased $0.2 million, primarily due to decreased sales of digital detectors for dynamic imaging applications partially offset by higher sales of CT X-ray tubes. Medical sales were particularly strong in CT, oncology, and dental modalities.
Industrial revenues increased
Table of Contents Gross Profit Three Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change % Change Medical
$ 54.3 $ 56.5 $ (2.2)(3.9) % Industrial 19.1 17.6 1.5 8.5 % Total gross profit $ 73.4 $ 74.1 $ (0.7)(0.9) % Medical gross margin 32.5 % 33.8 % Industrial gross margin 40.3 % 40.1 % Total gross margin 34.2 % 35.1 %
The decline in medical gross margin is mainly due to lower sales of digital detectors for dynamic imaging applications, higher transportation costs and higher material costs.
The Industrial segment gross profit increased primarily as a result of increased sales of digital detectors for dynamic imaging applications and non-destructive inspection applications, partially offset by higher freight and material costs. Operating Expenses Three Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change % Change Research and development
$ 20.2 $ 19.2 $ 1.05.2 % As a percentage of total revenues 9.4 % 9.1 %
Selling, general and administrative expenses
1.0 3.4 % As a percentage of total revenues 14.1 % 13.8 % Operating expenses
$ 50.4 $ 48.4 $ 2.04.1 % As a percentage of total revenues 23.5 % 22.9 %
Research and development
We are committed to investing in the business to support long-term growth and believe long-term research and development expenses of approximately 8% to 10% of annual revenues is the appropriate range that will allow us to innovate and bring new products to market for our global OEM customers. Research and development costs increased to 9.4% of revenues for the third quarter of 2022, primarily due to increased spending on material costs supporting research and development initiatives.
Selling, general and administrative expenses
Selling, general and administrative expenses for the third quarter of 2022 increased
$1.0 millionand increased to 14.1% of total revenues, primarily due to increased legal costs compared to the prior year.
Interest and other charges, net
The following table summarizes the Company's interest and other expense, net: Three Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change Interest income
$ 0.1$ - $ 0.1Interest expense (9.4) (10.6) 1.2 Other (expense) income, net (0.2) 0.2 (0.4)
Interest and other charges, net
Interest expense decreased due to the redemption of
Other (expense) income, net increased due to losses in certain investments in privately-held companies being higher for the three months ended
July 1, 2022, compared to the three months ended July 2, 2021, partially offset by reduced foreign exchange expense during the three months ended July 1, 2022compared to the three months ended July 2, 2021. 32
Income taxes (loss)
For the three months ended
July 1, 2022, we recognized income tax expense of $5.1 millionon $13.5 millionof pre-tax income. For the three months ended July 2, 2021, we recognized income tax expense of $3.1 millionon $15.3 millionof pre-tax loss. Our tax expense for the three months ended July 1, 2022increased primarily due to increased pre-tax income in certain jurisdictions, valuation allowance positions in the United Stateson deferred tax attributes, and losses in certain foreign jurisdictions for which no benefit can be recorded.
Discussion of operating results for the nine months ended
Compared to the nine months ended
Revenues Nine Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change % Change Medical
$ 493.2 $ 463.1 $ 30.16.5 % Industrial 134.8 128.7 6.1 4.7 % Total revenues $ 628.0 $ 591.8 $ 36.26.1 % Medical as a percentage of total revenues 78.5 % 78.3 % Industrial as a percentage of total revenues 21.5 % 21.7 % Medical revenues increased $30.1 million, primarily due to increased sales of CT X-ray tubes. The increase in medical sales was particularly strong in CT and oncology modalities.
Industrial revenues increased
Gross Profit Nine Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change % Change Medical
$ 153.7 $ 146.3 $ 7.45.1 % Industrial 55.3 49.6 5.7 11.5 % Total gross profit $ 209.0 $ 195.9 $ 13.16.7 % Medical gross margin % 31.2 % 31.6 % Industrial gross margin % 41.0 % 38.5 % Total gross margin % 33.3 % 33.1 %
The increase in the medical gross margin is mainly explained by the increase
Industrial gross margin increased primarily due to higher sales of X-ray tubes and digital detectors for dynamic imaging applications, partially offset by higher transportation and material costs.
Operating Expenses Nine Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change % Change Research and development
$ 56.8 $ 54.1 $ 2.75.0 % As a percentage of total revenues 9.0 % 9.1 %
Selling, general and administrative expenses
(5.6) (5.9) % As a percentage of total revenues 14.1 % 15.9 % Operating expenses
$ 145.4 $ 148.3 $ (2.9)(2.0) % As a percentage of total revenues 23.2 % 25.1 % 33
Research and development
We are committed to investing in the business to support long-term growth and believe long-term research and development expenses of approximately 8% to 10% of annual revenues is the appropriate range that will allow us to innovate and bring new products to market for our global OEM customers. Research and development costs remained at 9.0% of total revenues due to the relative increase in revenue as compared to the increase in research and development costs.
Selling, general and administrative expenses
Selling, general and administrative expenses for the nine months ended
July 1, 2022, decreased to 14.1% of sales primarily due to lower compensation costs, reduced external audit fees and higher revenue.
Interest and other charges, net
The following table summarizes the Company's interest and other income (expense), net: Nine Months Ended (In millions) July 1, 2022 July 2, 2021 $ Change Interest income $ 0.2 $ -
$ 0.2Interest expense (30.4) (31.3) 0.9 Other expense, net (3.0) (2.5) (0.5)
Interest and other charges, net
Interest and other expense, net decreased during the nine months ended
July 1, 2022due to the redemption of $27 millionof our Senior Secured Notes in March 2022and the redemption of $30 millionof our Senior Secured Notes in July 2021, as well as reduced fees on the ABL agreement.
Other expenses, net increase during the nine months ended
Taxes on Income (Loss) For the nine months ended
July 1, 2022, we recognized an income tax expense of $12.8 millionon $30.4 millionof pre-tax income. For the nine months ended July 2, 2021, the Company recognized income tax expense of $4.7 millionon $13.8 millionof pre-tax loss. Our tax expense for the nine months ended July 1, 2022increased, compared to the prior year, primarily due to pre-tax income in certain jurisdictions, valuation allowances in the United Stateson deferred tax attributes, and losses in certain foreign jurisdictions for which no benefit can be recorded.
Cash and capital resources
We assess our liquidity in terms of our ability to generate cash to fund our operations, including working capital and investing activities. We believe that our operating cash flow, cash on our balance sheet and availability under our ABL Facility are sufficient to meet our anticipated operating cash needs for at least the next 12 months and will be sufficient to allow us to continue to invest in our existing businesses, consummate strategic acquisitions and manage our capital structure on a short and long-term basis. We are currently not aware of any trends or demands, commitments, events, or uncertainties that will result in or that are reasonably likely to result in our liquidity increasing or decreasing in any material way that will impact our capital needs during or beyond the next 12 months. The maximum availability under our ABL Facility is
$100.0 million; however, the borrowing base under the ABL Facility fluctuates from month-to-month depending on the amount of eligible accounts receivable, inventory, and real estate. As of July 1, 2022the amount available under our ABL Facility was $97 million, and the ABL Facility remains undrawn. See Part II, Item 1A. "Risk Factors" for a further discussion. At July 1, 2022we had total debt of $412.6 millionnet of discounts and deferred issuance costs of $38.0 million. 34
The following table summarizes our cash and cash equivalents and marketable securities: (In millions) July 1, 2022 October 1, 2021 $ Change Cash and cash equivalents
$ 99.6$ 144.6 $ (45.0)Marketable securities not included in cash and cash equivalents 10.4 - 10.4 Total $ 110.0$ 144.6 $ (34.6)Borrowings
The following table summarizes the evolution of our outstanding debt:
July 1, 2022 October 1, 2021 (In millions, except for percentages) Amount Amount $ Change
Current long-term debt maturities
Other debt $ 2.5 $ 2.8
$ (0.3)Total current maturities of long-term debt $ 2.5 $ 2.8 $ (0.3)Non-current maturities of long-term debt: Convertible Senior Unsecured Notes $ 200.0$ 200.0 $ - Senior Secured Notes 243.0 270.0 (27.0) Other debt 5.1 7.8 (2.7)
Total non-current maturities of long-term debt:
$ (29.7)Unamortized issuance costs and debt discounts Unamortized discount - Convertible Notes $ (31.0)$ (37.6) $ 6.6Unamortized issuance costs - Convertible Notes (3.4) (4.1) 0.7 Unamortized issuance costs - Senior Secured Notes (3.6) (4.4) 0.8 Total $ (38.0)$ (46.1) $ 8.1Total debt outstanding, net $ 412.6$
$ (21.9)Cash Flows Nine Months Ended (In millions) July 1, 2022 July 2, 2021 Net cash flow provided by (used in): Operating activities $ (0.2) $ 42.0Investing activities (20.9) (12.9) Financing activities (24.0) (1.3)
Effects of exchange rate changes on cash and cash equivalents and restricted cash
(decrease) net increase in cash and cash equivalents and restricted cash
$ (45.2) $ 27.7Net cash (used in) provided by operating activities. Net cash (used in) provided by operating activities was $(0.2) millionand $42.0 millionfor the nine months ended July 1, 2022and July 2, 2021, respectively. The decrease in cash provided by operating activities was primarily due to increased purchases of inventory, partially offset by an increase in accounts payable. Net cash used in investing activities. Net cash used in investing activities was $20.9 millionand $12.9 millionfor the nine months ended July 1, 2022and July 2, 2021, respectively. The increase in cash used in investing activities was primarily due to the purchase of marketable securities during the nine months ended July 1, 2022. Net cash used in financing activities. Net cash used in financing activities was $24.0 millionand $1.3 millionfor the nine months ended July 1, 2022and July 2, 2021, respectively. The increase in cash used in financing activities was primarily due to the redemption of $27 millionof the Senior Secured Notes during the nine months ended July 1, 2022. 35
October 2013, we entered into an amended agreement with dpiX and other parties that, among other things, provides us with the right to 50% of dpiX's total manufacturing capacity produced after January 1, 2014. The amended agreement requires us to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. As of July 1, 2022, we estimate that we have fixed cost commitments of $6.6 millionrelated to this amended agreement through the remainder of calendar year 2022. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement). In October 2015, pursuant to a Domination and Profit and Loss Transfer Agreement (the "MeVis Agreement"), we committed to pay the noncontrolling shareholders of MeVis an annual recurring net compensation of €0.95 per MeVis share. The annual net payment will continue for the life of the MeVis Agreement, which we anticipate will continue for as long as we remain as the controlling shareholder of MeVis. As of July 1, 2022, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares. During the third quarter of fiscal year 2020, we entered into a purchase agreement with a supplier to acquire certain equipment and intellectual property from the supplier that is utilized to manufacture X-ray cables utilized in our products. As of July 1, 2022, there has been no transfer of control of the underlying equipment. This acquisition is expected to be completed during the 2022 fiscal year and the total consideration to be paid by us for the acquired assets is expected to be ¥1,084.7 million or approximately $8.0 million, subject to potential decreases for costs incurred by the Company. On April 14, 2022, we entered into a foreign currency hedge related to this Japanese Yen payment, which is expected to fix the purchase price of these assets at approximately $7.9 million. Contingencies From time to time, the we are a party to or otherwise involved in legal proceedings, government inspections, investigations, customs and duty audits, and other claims and contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. We accrue amounts for probable losses, to the extent they can be reasonably estimated, that we believe are adequate to address any liabilities related to legal proceedings and other loss contingencies that we believe will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. We did not have any material contingent liabilities as of July 1, 2022and October 1, 2021. Legal expenses are expensed as incurred.
Days of incredible deals
The number of days of sales outstanding (“DSO”) for customer accounts was 67 days at
Recent or updated accounting standards not yet in force
See Note 1, Summary of Significant Accounting Policies, of the notes to the accompanying condensed consolidated financial statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our condensed consolidated financial statements.
Backlog is the accumulation of all orders for which revenues have not been recognized and are still considered valid. Backlog also includes a small portion of billed service contracts that are included in deferred revenue. Our estimated total backlog at
July 1, 2022was approximately $456 million. Orders may be revised or canceled, either according to their terms or as customers' needs change. In addition, our ability to convert backlog into revenue may be impacted by on-going supply chain related interruptions and uncertainties. Consequently, it is difficult to predict with certainty the amount of backlog that will result in revenues. We perform a quarterly review to verify that outstanding orders in the backlog remain valid. Aged orders that are not expected to be converted to revenues are deemed dormant and are reflected as a reduction in the backlog amounts in the period identified. In addition to orders for which revenues have not been recognized and are still considered valid, we have pricing agreements with many of our established customers that span multi-year periods. These pricing agreements include volume ranges under which orders are placed. 36
© Edgar Online, source